AB — AB Science SA Share News
0.000.00%
Last trade - 00:00- €65.08m
- €73.85m
- €1.17m
French and Benelux stocks-Factors to watch
Brief: AB Science FY Net Loss Narrows To EUR 15 Mln
Brief: AB Science Says Phase 2B/3 Study Evaluating Masitinib In Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Met Primary Endpoint
Brief: AB Science Secures EUR 6 MLN In Non-Dilutive Financing Guaranteed By French Government
Brief: AB Science: Update On Masitinib Phase 3 Study (Ab12003)
Brief: AB Science: Independent Publication Sees Masitinib As Possible Alzheimer's Therapy
Brief: AB Science: New Independent Publication Confirms Role Of Masitinib As Potential Therapy In Pancreatic Cancer
Brief: AB Science: New Publication Says Masitinib Has Anti-Vital Activity Against SARS-CoV-2 Virus
Brief: AB Science Sets Issue Price Of 14.42 Euros Per New Share
Brief: AB Science Updates On Phase 2B/3 Study Evaluating Masitinib In Alzheimer’S Disease
Brief: AB Science: Phase 2B/3 Masitinib Study In Alzheimer's Disease Meets Primary Endpoint
Brief: AB Science: Confirmatory Phase 3 Study AB12005 With Masitinib In First Line Pancreatic Cancer With Pain Was Successful
Brief: EIB Supports AB Science In COVID-19 Development Programme
Brief: AB Science Secures Equity Financing For Maximum Of 4 Million Shares With Alpha Blue Ocean’S Pact
Brief: AB Science Announces 4.5 Million Euros Financing Via OCABSA Issuance
Brief: AB Science To Present Results From Masitinib Study Ab07015 At American Thoracic Society Symposium
Brief: AB Science H1 Net Loss Narrows At 8.8 Million Euros
Brief: AB Science Presents Phase 2B/3 Study Results For Masitinib
Brief: AB Science Says New Independent Research Reveals Masitinib Has Direct Anti-Viral Activity Against SARS-CoV-2 Virus In Vitro